About Us

Ferring is a Swiss-based research driven, specialty biopharmaceutical company active in global markets. The company identifies, develops and markets innovative products in the areas of endocrinology, gastroenterology, infertility, obstetrics, and urology. In recent years Ferring has expanded beyond its traditional European base, having now over 2500 employees worldwide and operating subsidiaries in over 40 countries. The U.S. company is based in Suffern, NY. To learn more about Ferring or our products please visit www.ferring.com.

Ferring R&D centers are located in San Diego (USA), Beer Tuvia (Israel) and Copenhagen (Denmark). Ferring R&D skills and expertise encompass peptide therapeutics, small molecule mimetics at peptide/hormone receptors, protease inhibitors and recombinant proteins.

Ferring Research Institute, Inc. (FRI, Inc.) was established in San Diego in 1996 as Ferring's peptide research center. FRI, Inc. is a fully integrated target and drug discovery unit, primarily focused on peptides, with capacity also in organic chemistry and protein discovery. Research programs have resulted in several clinical candidates, including degarelix, a peptidic GnRH antagonist for prostate cancer; barusiban, a peptidic oxytocin antagonist for preterm labor; and FE 200665/CR665, a peptidic kappa receptor agonist being developed by Cara Therapeutics for the treatment of pain. A new state of the art research facility is under construction.